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RECURRENCE OF ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL  
 
NEOPLASIA POST-TREATMENT IN HIV-POSITIVE WOMEN  
 
WAFAA ABBASI 
ABSTRACT 
BACKGROUND:  The incidence of anal cancer in HIV-positive (HIV+) women has 
increased in the past 3 decades. Anal cancer prevention strategies include the 
detection and treatment of high-grade squamous intraepithelial lesions (HSIL) of 
the anus (anal precancer) in order to prevent progression to anal cancer. Studies 
have evaluated the effectiveness of anal HSIL treatment in HIV+ Men who have Sex 
with Men (MSM); little is known about the effectiveness of treatment in HIV+ 
women. 
OBJECTIVE:    To determine the recurrence rate of anal HSIL in HIV+ women after 
ablative or topical treatment.  
METHODS: A retrospective chart review was performed on all HIV+ women seen at 
Boston Medical Center (BMC) between 2004 and 2017 who received treatment for 
anal HSIL and had at least one follow up visit with high-resolution anoscopy (HRA). 
The time to recurrence was measured as the time between the first treatment 
procedure to the date of biopsy-proven HSIL.  
RESULTS: 84 HIV+ women were diagnosed with anal HSIL. 48 (57%) had treatment 
of anal HSIL and at least one follow up anal evaluation and were included in the 
study. The median age of the study cohort was 53 years. The median follow-up time 
was 3.79 years, with a range of 0.44 to 13.39 years. 8 participants (16.67%) 
  v
received hyfrecation in clinic, 26 (54.17%) received ablation in the OR, 9 (18.75% 
received IRC, 2 (4.16%) received imiquimod, and 2 (4.16%) received 5-FU. HSIL 
recurrence occurred among 29 (60.4%) women. Mean time to recurrence of 25.4 
months (95% CI: 15.4-35.4). The probability of anal HSIL recurrence was 26% after 
12 months, 46% after 24 months, and 60% after 60 months (5 years). One (2%) 
study participant developed anal SCC.  
CONCLUSIONS: Recurrence rates of anal HSIL post-treatment are high in HIV+ 
women. This group would benefit from close surveillance and long-term follow up.   
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 1 
INTRODUCTION 
 Anal Cancer is a disease in which there is unregulated proliferation of cells in 
the anal canal. Most anal cancers are linked to infection with the Human 
Papillomavirus (HPV), the most common sexually transmitted infection globally. 
Anal cancer has many similarities to cervical cancer. Like cervical cancer, anal 
cancer is associated with HPV, frequently starts in the histological metaplastic zone 
between squamous and columnar epithelium, and frequently co-exists with anal 
HSIL. Because of these similarities, it is believed that the progression from anal HPV 
infection to anal cancer is analogous to that of the cervix. In the cervix, most HPV 
infections are transient; however, some HPV infections will persist and may cause 
changes in the epithelium termed high grade squamous intraepithelial lesions 
(HSIL), which may ultimately develop into cervical cancer. Prevention of cervical 
cancer includes the detection and treatment of cervical HSIL, preventing 
progression to cancer. Therefore, the management of HPV-associated lesions in the 
anal canal are modeled on the successful clinical management of cervical lesions in 
preventing progression to cancer. The vast majority of research conducted on anal 
cancer prevention has focused on the high-risk population of Human 
Immunodeficiency Virus-positive (HIV+) Men who have Sex with Men (MSM). 
Because HIV+ women are also at increased risk of developing anal cancer, it is 
important to develop anal cancer prevention strategies for this patient population.  
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Epidemiology 
 The American Cancer Society predicts that in 2018, in the United States, 
there will be 8,580 new anal cancer cases (5,620 in women and 2,960 in men) and 
1,160 anal cancer-related deaths (680 in women and 480 in men).1 Although a rare 
cancer, only currently accounting for 0.5% of new cancer cases in the United States, 
anal cancer rates have been on the rise in the past 4 decades. From 1975 to 2013, 
the incidence increased from 0.8 to 1.9 cases per 100,000 persons per year.2 Older 
individuals are at greater risk for developing anal cancer. The peak age range is 55-
64 years, with a median age of 60. Only 1.1% of anal cancers are diagnosed before 
age 35.3 Racial differences are also present, with the incidence greatest in White and 
lowest in Asian/Pacific Islander women.4 Survival from anal cancer is highly 
dependent on the stage at diagnosis. Based on data from the Surveillance, 
Epidemiology and End Results (SEER) program of the National Cancer Institute 
(NCI), from 2007 to 2013, the 5-year survival rate for anal cancer at all stages was 
66.9%. For cancers confined to the primary site (48% of total), survival was 81.3%. 
For cancers that spread to regional lymph nodes (32%), survival was 62.1%. For 
metastatic cancer (13%) survival was 29.6%.2  
Widespread implementation of national screening programs have proven 
successful in decreasing both the incidence and mortality rates of cervical SCC.5 
Because of the rising incidence of anal cancer and the pathophysiological and 
epidemiological similarities between anal and cervical cancers, a body of research 
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has been done in the past decade focusing on developing screening programs for 
anal cancer prevention.  
 There are certain known risk factors for anal cancer. Immunocompromised 
individuals, including those that are HIV+ or recipients of organ transplants are at 
greater risk. A study examining the incidence of anal cancer in HIV+ men and 
women between 1996 and 2012 found that individuals with HIV, including those 
with Acquired Immunodeficiency Syndrome (AIDS), are 19.1 times more at risk of 
developing anal cancer when compared to the general population.6 This relationship 
could be explained by the fact that as HIV infection progresses, the number of T-cells 
decline and HPV infection is cleared through a cell-mediated pathway involving T-
cells.4 A compromised immune system results in greater HR-HPV persistence in the 
anal canal, increasing the risk of developing anal precancer that might ultimately 
transition to cancer.  
Unlike several other opportunistic infections and cancers, anal cancer 
incidence did not decrease with the advent of highly active antiretroviral therapy 
(HAART), a treatment for HIV that uses a combination of drug therapies to 
effectively suppress the viral load, improving immune function. In fact, longer life 
expectancies for HIV+ individuals in the HAART era contributed to increased 
acquisition and persistence of anal HPV infection, contributing to increased anal 
cancer risk.7 Other risk factors include a history of cervical vaginal or vulvar cancer, 
genital warts, or high-grade cervical, vaginal or vulvar intraepithelial neoplasia (CIN, 
VAIN or VIN). Based on data from the SEER database, from 1973 to 2007, of the 
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189,206 cases of either in situ or invasive cervical vulvar or vaginal carcinoma, 255 
women developed anal cancer, indicating a 13-fold increase in anal cancer incidence 
when compared to the general population.8 The risk of developing anal cancer is 
also increased with cigarette smoking. A study determining relative risks for anal 
cancer by comparing various risk factors found that smoking more than 15 
cigarettes per day was associated with double the risk of anal SCC incidence.9 
 
 
 
 
Figure 1: Anatomy of the Anal Canal. The anal canal is nonkeratinizing squamous epithelium in between the 
columnar epithelium of the rectum and the keratinized squamous epithelium of the anal verge. Reprinted from 
The American Society of Colon and Rectal Surgeons (ASCRS) Textbook of Colon and Rectal Surgery (p. 184), 
by M. Luchtefeld and R. E. Hoedema, 2016, Arlington Heights, IL: Springer International Publishing. 
Copyright 2016 by Springer International Publishing. Reprinted with permission. 
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The Anal Canal 
The anal canal refers to the terminal end of the gastrointestinal tract. 
Surgically, it starts at the anorectal ring, a fusion of the puborectalis muscle, deep 
external anal sphincter and internal anal sphincter, located at the pelvic floor. The 
anal canal extends 3 to 4 centimeters distally to the anal verge, identified as the 
junction where the mucosal epithelium of the anal canal transitions to the cutaneous 
epithelium of the anal margin. The anal margin, or perianal skin, is the 5 centimeter 
region of squamous keratinized epithelial tissue around the anal verge, containing 
hair follicles and sweat glands. In the middle of the anal canal, is the dentate or 
pectinate line, a structure formed by transverse folds of the mucosa. This line 
divides the anal canal into an upper region (two thirds of the canal) and lower 
region (one third of the canal). Anatomically, the anal canal is the region between 
the dentate line and anal verge. 
 The anal canal can be divided into three histologically distinct regions. The 
colorectal zone (CRZ) is the region immediately distal to the rectum, measuring 1 to 
2 centimeters long. It consists of non-squamous epithelium, including simple 
columnar epithelium continuous with the rectal mucosa and transitional epithelium. 
The anal transformation zone (ATZ), also known as the intermediate or cloacogenic 
zone, is the region of squamous metaplasia immediately distal to the CRZ, consisting 
of four to nine layers of cells, including squamous, colorectal, and endocrine cells, 
melanocytes, and anal glands. The ATZ is the transitional region between the 
uninterrupted columnar mucosa, located proximally, to the uninterrupted 
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squamous mucosa located distally and is the region of the anal canal most 
susceptible to HPV infection. It starts at the squamocolumnar junction (SCJ) and  
 
 
ends at the dentate line. The basal layer of the ATZ consists of small cells with nuclei 
arranged perpendicularly to the basement membrane, while the surface layer 
consists of a variety of epithelial cells. The Squamous Zone (SQZ) lines the lower 
third of the anal canal, immediately inferior to the dentate line, extending to the anal 
verge. It consists of both non-keratinizing squamous epithelium and the squamous 
Figure 2: Micrographs of the Anal Canal: A: A longitudinal section of a fetal anal canal showing the 
three zones of the anal canal: Colorectal Zone (CRZ), Anal Transitional Zone (ATZ), and Squamous 
Zone (SQZ). B. A longitudinal section of the adult anal canal, showing the SQZ and TRZ. Adapted from 
“Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for 
anatomical differences in HPV-related cancer risk.” by E. J. Yang et al., 2015 Modern Pathology, 28(7), 
p. 994-1000. Copyright 2015 by Springer Nature. Adapted with permission.  
 7 
keratinized epithelium of the distal zone, free of hair, sebaceous glands and sweat 
glands.10 
Because of the complexity of this region, several different tumors can arise in 
the anal canal, with SCC being the most common. Tumors that arise from the CRZ 
are usually non-keratinizing SCC from transitional epithelium or adenocarcinomas 
from non-squamous epithelium.11 Tumors that originate from the ATZ include 
adenocarcinomas of the colorectal and anal glandular type, non-keratinizing SCC, 
neuroendocrine tumors (NET), and melanomas.10 Tumors from the squamous zone 
include SCC and the rare melanoma.  
When combined, keratinizing (also known as basaloid) and non-keratinizing 
SCC account for around 80% of tumors of the anal canal.10 Both types of SCCs 
behave similarly and are treated similarly.11 Adenocarcinomas are estimated to 
account for 10% of anal cancer incidences.10 However, it is possible that this is an 
overestimate due to misclassification of rectal adenocarcinomas as anal 
adenocarcinomas. Anal adenocarcinomas mostly arise from the region above the 
dentate line or in the anal margin, with the latter arising from anal glands or fistula 
tracts. They are treated similarly to rectal cancers. With the exception of SCC and 
adenocarcinomas, other tumors of the anal canal are relatively rare. 
 
Human Papillomavirus 
 HPV is a member of the Papillomaviridae family. Of the 189 known 
papillomavirus (PV) types, over 100 are human-PVs.12 However, not all HPV types 
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cause anal cancer. Of the five genera: alpha-, beta-, gamma-, mu- and nu-PVs; those 
that are responsible for anogenital and upper aero-digestive tract infections are 
mostly classified under the alpha-PV genus. HPV strains can be further divided into 
“low-risk” (LR) and “high-risk” (HR) types. HPVs 6, 11, 40, 42, 43, 44, 53, 54, 61, 70, 
72, 81, and 89 have been identified as LR-HPVs. Infection with LR-HPV types results 
in benign tumors, such as condylomas, or no detectable lesions, and are not 
expected to progress to malignant tumors even without treatment. HPVs 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 have been identified as HR-HPVs, and 
have the potential to cause malignant transformation. HPV types 16 and 18 account 
for 79% of anal SCC.13 
Due to the worldwide detection of HR-HPV strains in cervical carcinomas, it 
has been determined that HPV is a necessary cause of invasive cervical cancer 
worldwide.14 A review of the global health burden of infection-associated cancers 
found that HPV was responsible for 4.8% of all cancers diagnosed in 2008. Of the 
530,000 reported cases of cervical cancer in 2008, 100% were attributable to HR-
HPV infection. This strong correlation was independent of other risk factors and 
consistent in several different countries. The presence of HR-HPV in the tumor 
tissue of penile (50%), vulvar (43%), vaginal (70%) and anal carcinoma (88%) 
suggested that HR-HPV played a causal role in these cancers as well.15 The 23,760 
HPV-associated anal cancer cases diagnosed in 2008, were evenly distributed 
among developing and developed countries. The distribution of HPV-related anal 
 9 
cancer cases in males and females were 11,000 (45.8%) and 13,000 (54.2%) 
respectively.15 
 
Figure 3 Genomic organization of HPV16: Illustration of the genome of a high-risk HPV strain 
showing the upstream regulatory region (URR), early region and late region. Reprinted from 
“Epithelial Cell Responses to Infection with Human Papillomavirus” by M. A. Stanley, 2012, Clinical 
Microbiology Reviews, 25(2), p. 216. Copyright 2012 by the American Society for Microbiology. 
Reprinted with permission. 
 
HPV consists of a relatively small, circular, double stranded deoxyribonucleic 
acid (DNA) genome, 8 kb in size, surrounded by non-enveloped caspids. The genome 
of all HPV strains contain 3 regions: an upstream regulatory region (URR), a late 
region and an early region. The URR is a non-coding region that includes sequences 
that regulate DNA replication by transcription of protein-coding sequences in the 
early region. The late region contains sequences that code for L1, the major capsid 
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protein, and L2, the minor capsid protein. Together, these proteins form the 
structure of the virion that houses the DNA. The early region contains a series of 
open reading frames (ORFs) such as E1, E2, E4, E6 and E7. It determines the 
pathogenicity of the virus.13 
In mucosal tissue, HPV targets the cells that compose the basal layer of the 
stratified squamous epithelium. When the basal cells divide, they form new basal 
cells as well as transit amplifying cells that detach from the basal layer and make 
their way up to the surface layer, differentiating as they progress. In the basal cell, 
the viral DNA is maintained in a low-copy number. As the transit amplifying cells 
differentiate, the virus uses the host cell’s machinery for DNA amplification. As the 
host cell terminally differentiates and exits the cell cycle, proteins E6 and E7 
facilitate viral DNA replication. The genetic product of E6 and E7 genes are viral 
oncoproteins that extend the lifespan of supra-basal human keratinocytes and 
facilitate immortalization. E6 and E7 proteins from HR-HPV strains are 
constitutively expressed in tumors. Differentiation of HPV-infected cells result in 
dysplasia, which can progress to cancer. 
E7 is a multifunctional protein that binds to cell cycle regulatory proteins to 
alter their actions and allow for unscheduled cell cycle entry. One target of E7 is the 
tumor suppressing phosphorylated reintoblastoma protein (pRB), a key regulator of 
the E2F family of transcription factors. HR-HPV E7 interacts more efficiently with 
pRB and related “pocket proteins” p107 and p130 than LR-HPV E7. The E2F family 
plays a major role in the G1/S transition in the mammalian cell cycle. Binding of pRb 
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to E2F transcription factors prevents them from interacting with the cell’s 
transcription machinery and inhibits E2F-regulated gene expression. E7 targets pRB 
and other “pocket proteins” for ubiquitination and subsequent proteosomal 
degradation. The removal of the inhibiting influence on the E2F-regulated gene 
results in hyperproliferation.16 Other targets of E7 are histone deacetylases (HDAC). 
HDACs deacetylate lysine residues on histones, resulting in repression of 
transcription via chromatin remodeling. Interaction between E7 and HDAC 
specifically prevents HDAC from binding to the E2F2 promoter, resulting in active 
expression.17 E7 also binds to cyclin-dependent kinase (CDK) inhibitors p21 and 
p27, which are greater expressed when keratinocytes differentiate and lose contact 
with the basal layer. CDK2 when combined with Cyclin E or Cyclin A promotes the 
G1 to S progression. Binding of E7 to p21 and p27 allows the overriding of p21- and 
p27- mediated growth arrest.16 E7 is able to interfere with the mechanisms of 
telomere maintenance by the alternative lengthening of telomere (ALT) pathway to 
allow for tumor progression by extending the host cell’s lifespan.17 
The E7-mediated changes to the suprabasal epithelial layers results in p53-
mediated signals for growth arrest and/or apoptosis. The HR-HPV E6 protein 
mediates p53 ubiquitination and degradation via E6 associated protein (E6AP), an 
E3 ubiquitine ligase which blocks E7 apoptosis. E6-mediated degradation of PDZ 
proteins also occurs via E6AP, resulting in a loss of cell polarity and an increase in 
cell proliferation. HR-HPV E6 also induces expression of human telomerase reverse 
transcriptase (hTERT), the catalytic subunit of telomerase, contributing to the 
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immortalization of the host cell by maintaining telomere length.16 Through the 
cooperation of both the E6 and E7 proteins, the virus is able to disrupt the G1-S cell 
cycle checkpoint control and cause the cell to evade senescence.  
 
Natural history of anal HPV infections: 
Much of what we know about the development of anal cancer stems from 
research done on cervical cancer due to the common causative agent (HPV) and the 
cytological and histological similarities of HPV-associated damage in the anus and 
cervix. In the cervix, there is a SCJ, similar to, but not exactly like, the ATZ of the anal 
canal. This area is between two histologically distinct regions: the simple columnar 
epithelium of the endocervix and the nonkeratinized squamous epithelium of the 
exocervix. In both the anus and cervix, the transitional zones are highly susceptible 
to HPV infection and can develop HPV-related abnormalities in the epithelial tissue. 
In most cases, these abnormalities are transient. Some, however, progress to cancer. 
The Bethesda System, established in 1988, standardized classification of 
HPV-related abnormalities in the cervix to decrease variability of reported results 
and allow for a uniform standard for cytological interpretation.18 HPV-related 
abnormalities in the cervix can be referred to as dysplasia, cervical intraepithelial 
neoplasia (CIN), or atypical squamous intraepithelial lesions (ASIL). CIN is graded 
by increasing severity as CIN1, CIN2 or CIN3. Lesions are classified as LSIL when 
there is mild dysplasia, or CIN1, whereas moderate to severe dysplasia or carcinoma 
in situ, graded as CIN2 or CIN3, is classified as HSIL. In both the anus and cervix, 
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LSIL reflect active HPV replication and may resolve on its own or progress to HSIL, 
which reflects HPV-induced transformation with persistence of certain HR-HPV 
infection.19 HSIL are considered to be premalignant.  
 
Figure 4: Anal Epithelial Cells with Increasing Severity of Atypia. Illustration of epithelium of the 
anal canal showing the cellular changes associated with increasing grades of dysplasia. Reprinted 
from “Human Papillomavirus in the HIV-Infected Host: Epidemiology and Pathogenesis in the 
Antiretroviral Era,” by C. Brickman and J. M. Palefsky, 2015, Current HIV/AIDS Reports 12(1) p. 9. 
Copyright (2016) by Springer Science + Business Media. Reprinted with permission.  
 
The Lower Anogenital HPV-associated Squamous Terminology (LAST) 
project, conducted by the American Society of Colposcopy and Cervical Pathology 
(ASCCP) and the College of American Pathologists (CAP), provided evidence-based 
recommendations to standardize the classification of dysplasia along the anogenital 
tract.20 Because of the commonality between the HPV-associated lesions in 
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squamous sites of the lower genital tract in both men and women, it is 
recommended that the terminology used to diagnose the histopathology of the 
cervix be used to classify anal intraepithelial neoplasia (AIN) as well as other lesions 
of the anogenital tract.  
 
Anal Cancer Screening  
 Anal cancer screening is based on the success of cervical cancer screening 
programs. Implementation of these programs, which involve the detection and 
removal of precancerous lesions, significantly reduced the incidence and mortality 
of cervical cancer. A review of SEER data showed a 54% decrease in the incidence of 
invasive cervical cancer in the United States between the years 1973 and 2007.21 A 
similar study, based in Taiwan, measured the national disease burden of cervical 
cancer after the implementation of a national screening program in 1996 and found 
a 54.7% reduction in incidence between 1996 and 2007.22 This is mainly attributed 
to the introduction of the Papanicolaou Test in the 1940s. The Papanicolaou test, or 
“pap smear” is performed by collecting cells at the transformation zone of the cervix 
and examining them under a microscope to detect intraepithelial abnormalities 
associated with HPV. An abnormal cytology result is followed up with by a 
colposcopy, a diagnostic procedure in which a speculum is inserted into the cervix 
and 5% acetic acid is applied to the mucosal surface of the cervix, which is carefully 
viewed under magnification via colposcope for changes that suggest the presence of 
HSIL. Biopsies are taken of abnormal appearing lesions for further pathological 
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review. If the biopsies show cervical HSIL, treatment is performed with ablation or 
excision of the SCJ of the cervix. In 2012, the highest incidence rates of cervical 
cancer globally were found in medically underserved regions including parts of sub-
Saharan Africa, Latin America and the Caribbean, mainly due to lack medical 
infrastructure to support cervical cancer screening programs.23 
 
Figure 5: Proposed Screening Guidelines for High-Risk Populations Note, no formal guidelines 
currently exist for anal cancer screening. Screening consists of anal cytology, DARE, HRA with Biopsy 
and possible treatment. Reprinted from “Human Papillomavirus in the HIV-Infected Host: 
Epidemiology and Pathogenesis in the Antiretroviral Era,” by C. Brickman and J. M. Palefsky, 2015, 
Current HIV/AIDS Reports 12(1) p. 9. Copyright (2016) by Springer Science + Business Media. 
Reprinted with permission.  
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Anal Pap Test: 
One method of screening for anal cancer, adopted from cervical cancer 
screenings, is the use of cytology. Similar to the cervical pap test, the anal pap test is 
used to detect the presence of abnormal cells on the surface of mucosal tissue. The 
cells are collected via a moistened Dacron swab that is inserted into the anal canal 
and rotated along the length of the anal canal. The swab is then submerged in liquid 
cytology medium and agitated to disperse the cells in the vial. Debris such as mucus 
is removed from the sample and a thin layer of anal squamous cells are deposited on 
a microscope slide and stained using the Papanicolau stain for examination by a 
pathologist. Concurrent HPV testing may be performed to detect the presence of HR-
HPV DNA in anal epithelial cells. The anal pap test has been shown to be a reliable 
way to detect the presence of atypical-SIL but is limited in its diagnostic ability. In a 
study comparing the cytology results of 200 anal smears to the corresponding 
pathology reports of subsequent anal biopsies, it was found that anal smears had a 
98% success rate in detecting ASIL but were only able to predict the grade of 
abnormality of the biopsy 50% of the time. It was found that patients with cytology 
results that reported atypical squamous cells of undetermined significance (ASC-US) 
or LSIL had anal biopsies that showed HSIL 46-56% of the time.24 
Digital Anal Rectal Exam (DARE) and the High Resolution Anoscopy (HRA) 
Further examination of the anus includes the DARE and HRA. The DARE 
involves a provider inserting a lubricated and gloved finger into the anus to feel for 
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abnormalities such as thickened, raised, tender, hardened or ulcerated masses. The 
HRA is similar to the colposcopy used to screen for cervical cancers. During an HRA, 
a small plastic tube termed an anoscope is inserted into the anal canal to widen the 
area and the application of 5% acetic acid and Lugol’s iodine solution is applied to 
the mucosal surface to allow for the detection of A-SIL under magnification via a 
colposcope. Positioning of the anoscope allows for visualization of different regions 
of the anal canal, including the ATZ.  
The normal appearance of anal epithelium is shiny, translucent and pink. The 
application of acetic acid removes the superficial mucus layer and the acid 
penetrates into the cells of the surface layer of the epithelium. Physical changes that 
occur in these cells include dehydration of the intracellular compartment as well as 
coagulation of intracellular proteins. This alters the appearance of cells when 
exposed to light.25 In the normal stratified squamous epithelium, the surface layer is 
composed of squamous keratinocytes that are flat and contain small nuclei. The 
application of acetic acid does not significantly change the appearance of these cells 
and under magnification the epithelium maintains its pink color. The SCJ contains a 
variety of cell types, including cells that are transitioning from the simple columnar 
tissue of rectal epithelium to the stratified squamous epithelium of the anal canal. 
These cells typically have large nuclei and more protein in their intracellular 
compartments. With the application of acetic acid, the cells of the SCJ become 
denser, reflecting more light, and appear slightly grey under magnification. HPV-
infected cells have large nuclei as well and the intracellular compartment is filled 
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with viral proteins. Depending on the HPV type, the infection can involve the entire 
thickness of the epithelium. With the application of acetic acid, this region appears 
dense and absorbs light poorly.25 The term “acetowhite epithelium” describes such 
regions that are perceived as white due to the poor light reflection. Staining with 
Lugol’s iodine solution further differentiates HSIL and LSIL and helps determine the 
margin of disease. Lugol’s iodine solution is a dark brown liquid and is taken up by 
glycogenated cells such as normal anal epithelium. ASIL, especially HSIL do not 
contain glycogen and do not stain.25 HRA-directed biopsies are able to take 
advantage of the physical characteristics of the tissue after application of acetic acid 
and Lugol’s solution to identify regions of suspected HSIL. Histopathology then 
reliably confirms the diagnosis.  
 
Treatment Modalities 
It is hypothesized that therapeutic management of anal HSIL is effective in 
reducing the risk of progression to anal cancer, as is the case with cervical HSIL. The 
Anal Cancer HSIL Outcomes Research (ANCHOR) study conducted by the AIDS 
Malignancy Consortium (AMC) is an ongoing prospective trial that aims to discover 
if this is indeed the case by randomizing 5,085 HIV+ men and women diagnosed 
with anal HSIL into either an active monitoring or treatment arm to compare the 
incidence of anal cancer in both groups.  
Unlike the treatment of cervical HSIL, which involves either ablation or 
excision of the entire SCJ, treatment of anal HSIL is only directed at the HSIL lesions. 
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Treating the entire anal SCJ is not an option due to complications such as scarring 
and stenosis. The course of treatment largely depends on size, number, location and 
grade of the ASIL. Other contributing factors include the availability of resources, 
the patient’s likely adherence to treatment and anticipated treatment-related side 
effects.26  
Although no standard of care currently exists, several medical and surgical 
interventions have been developed in the past decade to treat anal HSIL. HRA-
guided procedures, such as infrared coagulation and electrocautery can be 
performed on an outpatient basis or in the operating room, and allow for ablation or 
fulguration of high grade lesions while preserving the deeper layers of tissue. In 
infrared coagulation, pulses of infrared light are applied to the lesions via a probe 
resulting in thermal coagulation and tissue necrosis. Hemostasis is achieved 
spontaneously. In electrocautery or hyfrecation, an electric probe is applied to the 
lesions to cauterize the tissue. Both methods allow for targeting lesions specifically. 
Another alternative are patient-applied topical creams, 5-Flurouracil (5-FU) and 
Imiquimod for treating extensive HSIL. 5-FU is an antimetabolite that interferes 
with the synthesis of DNA. Imiquimod is an immunomodulating agent with antiviral 
and antitumor properties.26 Surgical excision is another option to treat HSIL but this 
procedure is not ideal for patients with extensive or multifocal HSIL and may have 
adverse outcomes related to anal function. 
Due to the rising incidence of anal cancer in high-risk populations, it is 
increasingly important that screening, monitoring and treatment of anal HSIL be 
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standardized. Although several treatment modalities exist to treat anal HSIL, these 
lesions often persist or recur and follow up care is necessary. Studies determining 
the recurrence rate of anal HSIL in HIV+ populations largely focus on MSM. Data on 
recurrence rates for HIV+ women is limited and determining cost and medically 
effective management of anal HSIL, including follow up care, from data extrapolated 
from studies focusing on MSM is not ideal. This study will contribute necessary 
information for the development of guidelines for screening and treating anal HSIL 
in HIV+ women.     
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METHODS 
 
Data Source and Patient Selection 
 With approval from the institutional review board after expedited review at 
Boston Medical Center (BMC) and in accordance with the Health Insurance 
Portability and Accountability Act (HIPAA), a retrospective chart review was 
performed of all HIV+ women diagnosed with anal HSIL (AIN 2 or 3) at BMC from 
the start of anal screening with HRA in 2004 to the year of our request, 2017.  
We identified 90 patients through BMC’s Clinical Data Warehouse (CDW). 
After receiving our preliminary data set, we sorted through the list of patients using 
the matrix shown in Figure 6. The electronic medical charts of the study population 
identified went through a preliminary review to confirm eligibility based on our 
inclusion/exclusion criteria. Eligible subjects had to be female, have a diagnosis of 
HIV, and a pathology report confirming diagnosis of anal HSIL (AIN2 or AIN3). This 
review excluded 6 subjects: 4 were found to have anal cancer along with HSIL for 
their baseline pathology report, 1 had a pathology report of AIN1 that could not rule 
out HSIL and 1 was a male to female transgender.  Additional inclusion criteria 
included having treatment for anal HSIL and at least one follow-up visit following 
anal HSIL treatment that included HRA. Participants that were never treated (n=24) 
or had no follow-up after treatment (n=12) were also excluded. A total of 48 
patients were included in this study.  
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Figure 6: Flowchart of patient inclusion and exclusion 
 
CDW Data Query: HIV+ 
Women, AIN2, AIN3 
(n=90)
HIV+ Women with 
AIN2/3 (n=84)
Treated 
participants (n=60)
Treated participants 
with at least 1 follow up 
visit  (n = 48)
Excluded:
Lost to follow up after 
treatment (n=12)
Excluded: 
Lost to follow up after 
diagnosis (n=13)
Monitoring arm of 
ANCHOR study (n=6)
Refused treatment 
(n=2)
HSIL resolved without 
treatment (n=2)
Died (n=1)
Excluded:
Transgender M>F 
(n=1)
Anal Cancer (n=4)
AIN1 (n=1)
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Demographic and Clinical Data  
A master list of medical record numbers (MRN) linked to subject 
identification numbers for participants that met inclusion and exclusion criteria was 
maintained during data collection. Informed consent was waived by the IRB. 
Demographic and clinical information of eligible participants was obtained from the 
BMC electronic medical record (EMR) system. A manual chart review of eligible 
patients was sequentially performed and data was collected in REDcap, a secure 
web-based data management and survey tool.  
The initial dataset included relevant demographic information (age, 
ethnicity, race, marital status, and country of origin) and baseline clinical 
information (smoking status, year of HIV diagnosis, history of AIDS defining 
illnesses, nadir CD4 count and HPV medical history (history of HPV vaccine, 
anogenital dysplasia diagnosis and treatment). Subjects were then followed from 
their initial visit, defined as the date of diagnosis of HSIL, to either their last anal 
evaluation or to the diagnosis of anal cancer, whichever came first. Data was 
obtained from progress notes and corresponding lab reports. Data obtained 
included anal, cervical and vaginal cytology, HR-HPV testing, anal pathology, status 
of anti-retroviral therapy (ART) compliance, absolute CD4 count, and records of any 
treatments for anal HSIL or non-anal HPV-associated dysplasia.  
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Recurrence 
 For the purposes of this study, anal HSIL persistence and recurrence were 
considered identical. Recurrence was defined as biopsy-proven HSIL following 
treatment for anal HSIL. A histological diagnosis of HSIL was defined as all AIN2 or 
AIN3 lesions. Time to recurrence was measured in months from day of first 
treatment to recurrence or until censoring occurred.  
 
Statistical Analysis 
 Statistical analyses were performed using the Statistical Analysis System 
(SAS) v 9.4 (SAS Corp., Cary, NC, USA).  Categorical variables were described as 
number and percentage. Continuous variables were described using mean (standard 
deviation), median and range. 95% CIs were calculated for the mean time to 
recurrence. The probability of recurrence was determined by the Kaplan-Meier 
estimate for cumulative incidence. Patients lost to follow up or patients who did not 
recur by their last visit were censored.  
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RESULTS 
 From January 2003 through June 2017, 84 HIV+ women were diagnosed with 
anal HSIL at BMC. Of these 84 women, 36 were excluded due to loss of follow up or 
no history of treatment. Figure 6 details the inclusion and exclusion of study 
participants. A total of 48 patients met inclusion criteria and were included in this 
study. Table 1 describes the demographic data of the study cohorts. All patients 
were female, 30 (62.5%) were African American or Black and 32 (68.1%) were 
single. The median age of participants was 53 years with a range of 35-66 years.  
Table 2 describes the baseline clinical information of the study cohort. At the 
age of anal HSIL diagnosis, participants had been living with HIV for an average of 
12.64 years. Patients with any history of smoking accounted for 68.7% of the 
population. Nadir CD4 counts averaged at 211 cells/mm3 (SD 205.15) with 58% of 
participants with a nadir CD4 count of less than 200. Only 14.6% of the population 
had a history of AIDS defining illnesses and 95.8% were currently on HIV 
medication. At their baseline visit, study participants had an average absolute CD4 
count of 506.22 (SD 330.67) with a range of 78 to 1853. Of the 48 participants, 47 
(98%) did not receive the HPV vaccine in the past. Of the reported cases of HPV-
related dysplasia (23.91% with VIN2/3, 2.1% with VAIN2/3, 50% with CIN2/3 and 
15.2% with genital warts), treatment was received for 100% of VIN2/3 and 
VAIN2/3, 95.65% of CIN2/3 and 57.13% of genital wart cases.   
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Table 1: Participant Demographics (N=48)  
 
Measure n % 
Ethnicity   
 Hispanic/Latino 13 27 
 Not Hispanic/Latino 35 73 
Race   
 Black or African American 30 62.5 
 White 10 20.8 
 Unknown 8 16.7 
Place of Origin   
 North America 26 54.2 
 South America 2 4.2 
 Africa 10 20.8 
 Europe 1 2.1 
 Unknown 9 18.8 
Age in years   
 30-39 2 4.2 
 40-49 15 31.3 
 50-59 21 43.8 
 60-69 10 20.8 
Marital Status   
 Single 32 68.1 
 Married 10 21.3 
 Divorced 4 8.5 
 Widowed 1 2.1 
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Table 2: Baseline Clinical Information 
 
Measure n % 
Age at HSIL Diagnosis (years)   
 Mean 51.75 (7.86)  
 Median 53  
 Range 35-66  
Year of HIV diagnosis   
 1980-1989 8 18 
 1990-1999 19 42 
 2000-2009 16 35.6 
 2010-2018 2 4.4 
Years of HIV at HSIL Diagnosis   
 Mean 12.64 (8.64)  
 Median 12  
 Range 0 - 30  
Nadir CD4   
 Mean 211 (205.15)  
 Median 181  
 Range 2-931  
 > 200 20 41.7 
 < 200 28 58.3 
CD4 at HSIL Diagnosis   
 Mean 506.2 (330.7)  
 Median 447.5  
 Range 78-1853  
 > 200 41 85.4 
 < 200 7 14.6 
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Table 2: Baseline Clinical Information Continued 
 
 
Measure n %  
   
History of Genital Dysplasia (reported)   
 VIN 2/3 11 23.91
 VAIN 2/3 1 2.17
 CIN 2/3 23 50.0 
 Genital Warts 7 15.22
 
History of Treatment for Dysplasia (reported) 
 
 VIN 2/3 11 100 
 VAIN 2/3 1 100 
 CIN 2/3 22 95.65
 Genital Warts 4 57.13
Smoking History   
 Never Smoker 13 28.3
 Current Smoker 22 45.8
      0-20 pack years 10 45.5
      20-40 pack years 6 27.3
      41+ pack years 3 13.6
      Unknown 3 13.6
 Past Smoker 11 22.9
      0-20 pack years 6 54.5
      20-40 pack years 2 18.2
      41+ pack years 0 0 
      Unknown 
 Unknown 
3 
2 
27.3
4.2
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Table 2: Baseline Clinical Information Continued 
 
 
Measure n %  
  
History of HPV Vaccine   
 Yes 1 2 
 No 47 98 
History of AIDS Defining Illness   
 Yes 7 14.6 
 No 41 85.4 
Currently on HIV medication    
 Yes 46 95.8 
 No 2 4.2 
 
 Study participants were followed for an average of 3.79 years (SD 2.97) from 
the date of anal HSIL diagnosis to the date of last follow up, and had an average of 
7.85 anal evaluations (SD 4.92) during this time with a range of 2 to 22 visits. 
Treatment occurred on the day of HSIL diagnosis for 10 participants (20.8 %). The 
other 38 participants (79.2%) received their first treatment at a follow up visit. Days 
between diagnosis and treatment of anal HSIL averaged 204.7 days (SD 354.54) and 
ranged between 0 and 1890 days. For the first treatment procedure, 8 participants 
(16.67%) received hyfrecation in the clinic, 26 (54.16%) received ablation in the OR, 
9 (18.75%) received IRC, 2 (4.16 %) received imiquimod, and 2 (4.16 %) received 5-
FU. Participants were treated an average of 1.98 (SD 1.31) times after diagnosis of 
HSIL, with a range of 1-5 times during the period they were being followed. One 
 30 
participant developed anal SCC during follow up.  Visit details are summarized in 
table 3.  
Table 3: Visit Information (N=48)  
Measure n % 
Number of Visits   
 Mean 7.85 (4.92)  
 Median 6 (4.5 – 10.5)  
 Range 2-22  
Years in Follow up   
 Mean 3.79 (2.97) 
 Median 2.62 (1.56 -5.51)  
 Range 0.44-13.39  
Days Between Diagnosis and Treatment   
 Mean 204.67 (354.54)  
 Median 87.5 (41.5-189)  
 Range 0-1890  
Number of treatments after diagnosis   
 Mean 1.98 (1.31) 
 Median 1  
 Range 1-5  
Time to first recurrence (days)  (n=29, 60.4 %)  
 Mean 772.9 
 Median 441 (194-1061)  
 Range 91-3325  
Type of treatment   
 Hyfrecation in clinic 8 16.67 
 Ablation in OR 26 54.16 
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Of the 48 women included in the study, recurrence occurred in 29 (60.4%) 
participants, with a mean time to recurrence of 25.4 months (95% CI 15.4 – 35.4). 
Figure 7 demonstrates the probability of recurrence over time. The Kaplan Meier 
curve predicted that the probability of anal HSIL recurrence was 26% at 12 months, 
46% at 24 months, 53% at 36 months, and 60% after 48 and 60 months. 
Table 3: Visit Information (N=48) (Continued) 
Measure n % 
Type of treatment (Continued)   
 IRC 9 18.75 
 Imiquimod 2 4.16 
 5-FU 2 4.16 
 Other 1 2.08 
Baseline Anal Cytology (n=25)   
 Normal 8 32 
 ASC-US 8 32 
 LSIL 5 20 
 HSIL 4 16 
Baseline anal HR-HPV(n=15)   
 Yes 12 80 
 No 3 20 
 32 
 
Figure 7: HSIL Recurrence in HIV-positive women after anal HSIL treatment 
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DISCUSSION 
 
 With the increase of anal cancer incidence in the past few decades, there is a 
strong need to develop a standardized approach for management of anal HSIL. Most 
research on the effectiveness of anal HSIL treatment in the HIV+ population has 
been done on HIV+ MSM and little is known about anal HSIL management in HIV+ 
women. In this retrospective study, we followed 48 HIV+ women that received 
either topical or ablative treatment for anal HSIL and we were able to demonstrate 
that the post-treatment recurrence rate of anal HSIL in HIV+ women is high.  
 Increasing evidence supports that anal cancer is preceded by HSIL. 
Retrospective studies show an 8.5 to 13% progression to anal SCC when HSIL is 
monitored but not treated.27 It is hypothesized that the cervical cancer model of 
treatment or removal of HSIL to prevent the progression to cancer in the cervix can 
successfully be applied to the anal canal to prevent anal cancer. In our study, one 
person out of the 48 followed (2.08%) unfortunately developed anal SCC. We expect 
that this number would have been higher had we observed HIV+ women that were 
being monitored but not treated. This individual was a 40-year-old female with a 
history of AIDS defining illness, anal fistulas and abscesses, VIN3, and CIN3, who 
received treatment of anal HSIL via ablation in the OR. She was later found to have a 
cancerous mass near the internal opening of an anal fistula tract.  
In our study, patients who received treatment for anal HSIL were at high risk 
for recurrence. The median time to recurrence was 14.5 months after treatment. A 
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total of 60.4% of our 48 participants recurred during follow up. The probability of 
recurrence was 24.5% at 12 months and 59% at 60 months. Because of the limited 
data available for the effectiveness of anal HSIL treatment in HIV+ women, we 
compared our data with data from studies looking at the effectiveness of anal HSIL 
treatment in HIV+ MSM as well as the general HIV+ population. These studies varied 
in study design, treatment modalities, definitions of recurrence and outcomes 
measured (HSIL vs ASIL), duration and method of follow up. This was taken into 
consideration when comparing the information to our results.  
The first prospective study of the surgical management of anal HSIL, 
conducted by Chang et al. in 2002, followed 29 HIV+ MSM that received ablation in 
an OR setting and found that 79% had persistent/recurrent HSIL with a mean time 
to recurrence of 12 months, with risk of recurrence approaching 100% by 50 
months.27 The time to recurrence was similar to our median time of 14.5 months. 
This study only included participants with a large volume disease and this may have 
contributed to the high recurrence rate. In 2016, Burgos et al studied the 
effectiveness of in-office electrocautery ablation of anal HSIL in HIV+ MSM and 
found 25.5% recurrence and 33.7% persistence. It was estimated that the 
probability of recurrence was 27.6% at 12 months and 48.3% at 24 months.28 The 
study involved multiple ablative treatments as opposed to our study which followed 
patients after one course of treatment.  
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Studies have shown that treatment outcomes and overall recurrence rates 
for IRC and electrocautery ablation are similar. Goldstone et al. compared anal HSIL 
recurrence rates after IRC ablation in 44 HIV+ and 52 HIV- MSM and found that 
HIV+ MSM were 1.9 times more likely than HIV- MSM to recur after their first IRC 
treatment. They also determined that HIV+ MSM had recurrences twice as quickly as 
HIV- MSM, with a median time to recurrence in HIV+ MSM of 12 months and HIV- 
MSM of 24 months.26 Recommendations from this study suggested that HIV status 
be a factor when determining the length of surveillance intervals after IRC. Marks 
and Goldstone followed 132 HIV+ MSM that received in-office electrocautery and 
found 63% of HIV+ MSM recurred over a median of 20 months, similar to earlier 
data regarding treatment outcomes after IRC.29 Although we did not look at the 
different treatment modalities separately due to the small sample size, the overall 
recurrence rate is consistent with these findings.  
In a retrospective study looking at the effectiveness of IRC in both HIV+ men 
and women, Sirera et al. found only 7 patients out of 56 (12.5%, 2 women and 5 
men) had recurrence of anal HSIL after a mean follow up of 25 months post- IRC 
treatment. It should be noted that the evaluation of recurrence was by cytology and 
DARE; given the known poor correlation of anal cytology for the detection of anal 
HSIL, it is likely that the results represent a lower bound estimate. In addition, the 
study explained the low recurrence rate by the characteristics of the study 
population: most patients had only one high-grade lesion to treat and had good 
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immunological status.30 The immunological statuses of our study participants were 
more assorted. 58.3% had a nadir CD4 of less than 200, 14.6 % had a history of an 
AIDS defining illness, and years of HIV diagnosis at the time of HSIL diagnosis 
ranged from 0 to 30.  
Unlike the similarity between electrocautery and IRC treatment outcomes, 
past research shows that the recurrence rate of topical treatments tends to be 
consistently higher than ablative treatments. Richel et al. compared treatment 
response between imiquimod (n=24), 5-FU (n=16) and electrocautery (n=10) in 
HIV+ MSM in a randomized controlled trial where participants were assigned to 
receive either intra-anal or perianal treatments for 16 weeks via imiquimod, 5-FU or 
electrocautery. A complete response occurred in 13 out of the 54 patients (24%) in 
the imiquimod group, 8 of the 48 (17%) in the 5-FU group and 18 of the 46 (39%) 
patients in the electrocautery group. No response occurred in 26 (48%) patients in 
the imiquimod group, 29 (60%) in the 5-FU group and 15 (33%) in the 
electrocautery group.  Recurrence occurred in 22 out of 48 (46%) participants with 
responses. This included 47% of patients assigned to the imiquimod arm, 50% 
assigned to 5-FU and 43% assigned to electrocautery. It was shown that imiquimod 
and 5-FU had lower complete responses and higher recurrence rates when 
compared to electrocautery. Perianal AIN responded better to the topical 
treatments than intra-anal AIN.31 Unlike our study, this study included, and grouped 
together, participants with low-grade and high-grade lesions, making it difficult to 
 37 
compare our recurrence rates to theirs. Also unlike our study, participants in the 
electrocautery group received multiple treatments as opposed to one in-office or OR 
procedure.  
Limitations 
 Our small sample size and the relatively short follow up for a number of 
patients reduced the power of our study and increased the margin of error. Our 
sample size was limited due few number of people diagnosed with HSIL as well as 
the number of patients that were lost to follow up. Between 2004 and 2017, only 84 
HIV+ women were diagnosed with anal HSIL at BMC. Patients were excluded from 
analysis due to being lost to follow up either after diagnosis or immediately after 
treatment. Inclusion criteria only required that participants had at least one follow 
up visit after treatment. Some patients were followed for only a short amount of 
time, reducing the sample size available as the time from treatment increased. A 
larger cohort being followed for a greater amount of time would have led to more 
significant findings. Moreover, our study only includes patients that were seen at 
BMC and it is not known if these findings are generalizable other populations of 
HIV+ women.    
Because recurrence was determined by biopsy-proven HSIL, the rate of 
recurrence may have been underestimated due to HSIL present that was not 
detected during the HRA, patients deferring HRA and biopsies during their anal 
evaluation, or patients missing visits. Since the size of the lesions or presence of 
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multifocal lesions were not recorded, we were unable to assess the impact this 
information had on recurrence rates.  
 
Future Directions 
 Because of the small sample size, we were unable to look at the impact 
potential factors such as length of HIV at anal HSIL diagnosis and nadir CD4 counts 
on treatment outcomes. Future studies could analyze the impact of such factors to 
determine if a patient’s baseline clinical data has a significant impact on treatment 
outcomes.  
  Studies have shown that despite high recurrence rates, there is a decrease in 
incidence of anal HSIL with multiple ablative treatments.32 Our study only looked at 
outcomes following the first treatment of anal HSIL but it would be informative to 
see recurrence rates following the second and third treatments. Additionally, this 
study looked at several different treatment modalities but did not differentiate 
between them during data analysis. Given a larger sample size, future studies can 
look at the treatment-specific recurrence rates and determine if one mode of 
treatment results in a longer recurrence-free survival than the others.  
 Possible future steps could include determining the effect of the qHPV on 
anal HSIL recurrence in HIV+ women. Studies suggest that the Quadrivalent Human 
Papillomavirus (qHPV) vaccine reduces the rate of recurrence of anal HSIL in MSM 
and cervical, vulvar and vaginal HSIL in women.33 However, a recent prospective 
trial found that qHPV vaccination of adults with HIV did not prevent persistent anal 
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HPV infections nor improve anal HSIL outcomes, although it was possible that there 
might have been improved outcomes with longer follow up.34  
  
Conclusion 
Because of the high recurrence rates in HIV+ women, this high-risk 
population would benefit from close surveillance, similar to HIV+ MSM. 
Furthermore, as can be seen in our survival analysis, probability of recurrence 
approaches 100% over time, suggesting that long-term recurrence-free survival is 
unlikely in HIV+ women and this population needs long-term follow up.  
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